Diode Laser 940 nm in Management of Loss of Taste Sensation

Diode Laser 940 nm in Management of Loss of Taste Sensation in Patients With Post COVID Syndrome

Sponsors

Lead Sponsor: Fayoum University

Source Fayoum University
Brief Summary

The global pandemic has recently emerged by transmission of SARS-CoV2 virus. The virus has had a massive impact on health, wealth and social aspects worldwide. Since the identification of this virus in Wuhan, China, millions of cases has been diagnosed worldwide with mortality rates ranging from 3% to 12 %

Detailed Description

'Long COVID' is emerging as a phenomenon where patients have long-term unresolved symptoms (8,9). These could be prolonged symptoms of COVID-19 or a posteCOVID-19 syndrome for which dysfunction of smell and taste sensation has been proposed. The proposal presents the diode laser 940 as possible treatment for the loss of taste sensation in patients with long COVID. The effect of low levels of laser energy was first discovered by Dr Endre Mester in 1967.5 Since then it has been used for various applications in the field of medicine and dentistry and is broadly termed 'low level laser therapy'(LLLT) or 'biostimulation' or 'phototherapy'. It is defined as a 'non-thermal' laser light application using photons (light energy) from the visible and infrared spectrum for tissue healing and pain reduction (North American Association of Laser Therapy-NAALT). Several in vitro studies have demonstrated that the effects of laser light on wound healing are much greater than obtained with light from other sources, such as light-emitting diodes (LEDs).(10-13)

Overall Status Not yet recruiting
Start Date April 15, 2021
Completion Date June 1, 2021
Primary Completion Date May 20, 2021
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
taste sensation survey 6 weeks
Enrollment 150
Condition
Intervention

Intervention Type: Device

Intervention Name: a 940-nm diode laser

Description: a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.

Arm Group Label: group I

Eligibility

Criteria:

Inclusion Criteria: A diagnosis of SARS-CoV2 with PCR. Age range from 18-60 years old Loss of taste sensation Exclusion Criteria: Pregnancy or contraceptive pills Lactation Any auto-immune disease that could affect the oral mucosa On any neoplastic therapy. Uncontrolled diabetes.

Gender: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Healthy Volunteers: No

Overall Contact

Last Name: Alshaimaa Mohamed, PhD

Phone: +201006047940

Email: [email protected]

Verification Date

March 2021

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Fayoum University

Investigator Full Name: Alshaimaa Ahmed shabaan

Investigator Title: associate professor in oral & maxillofacial Surgery Department

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: group I

Type: Experimental

Description: a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.

Label: group II

Type: No Intervention

Description: No treatment

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Intervention Model Description: Patients with SARS-CoV2 infection confirmed with PCR with loss of taste sensation

Primary Purpose: Treatment

Masking: Double (Participant, Outcomes Assessor)

Source: ClinicalTrials.gov

Clinical Research News